51˶

Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence

— News and commentary from the world of neurology and neuroscience

MedpageToday
Neuro Break over a computer rendering of neurons.

Why is , an investigational anti-amyloid agent for early Alzheimer's disease, facing an approval delay? (The Guardian)

Early use of erenumab (Aimovig) compared with oral migraine preventives in treatment-resistant episodic migraine. (JAMA Neurology)

Net sales for eteplirsen (Exondys 51), golodirsen (Vyondys 53), and casimersen (Amondys 45) -- three genetically targeted therapies for Duchenne muscular dystrophy that received accelerated approval but of efficacy -- totaled $3.1 billion from 2016 to 2022. (JAMA)

Common disinfectant and flame retardant chemicals in mice and in a human organoid model of prenatal cortical development. (Nature Neuroscience)

Early resulted in significantly elevated postconcussive symptoms, which persisted 3 months after injury in some children. (JAMA Network Open)

The U.S. Government Accountability Office looked at to help diagnose Alzheimer's, Parkinson's, and other neurodegenerative diseases.

Experts weighed in as the newly approved for opioid addiction prepares to roll out. (Washington Post)

The Alzheimer's Disease Sequencing Project identified 17 variants within five genomic regions. (Alzheimer's and Dementia)

The with attention deficit-hyperactivity disorder (ADHD) was 11.3% in children ages 5-17 years during 2020-2022, the CDC said. (NCHS Data Brief)

The complement inhibitor ravulizumab (Ultomiris) earned another indication, this time for adults with anti-aquaporin-4 antibody-positive , AstraZeneca said.

Physical activity significantly reduced the both in acute COVID-19 and post-COVID condition in young women. (Scientific Reports)

The prion disease of women in the Eastern Highlands of Papua New Guinea. (American Journal of Human Genetics)

  • Judy George covers neurology and neuroscience news for 51˶, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.